38 results about "Parathyroid Tetany" patented technology

[Problem] To provide a compound which can be used for treating diseases in which a calcium sensing receptor (CaSR) participates, particularly hyperparathyroidism.[Means for Resolution] It was found that a novel piperidine derivative which is characterized in that one of a 3-position and a 4-position is substituted with an aminomethyl group substituted with an arylalkyl group or the like and the other position is substituted with aryl, heteroaryl or the like, or a salt thereof, has an excellent CaSR agonistic regulatory action, and also has excellent selectivity with a CYP2D6 inhibitory action having a possibility of causing drug interaction. Based on the above, this novel piperidine derivative is useful as a therapeutic agent for diseases in which CaSR participates (hyperparathyroidism, renal osteodystrophy, hypercalcemia, and the like).

Disclosed are methods of inhibiting bone resorption and / or promoting bone formation using GLP-2 and related Compounds. The invention has a wide spectrum of important uses including hyperparathyroidism, Paget's disease, hypercalcemia of malignancy, osteolytic lesions produced by bone metastasis, bone loss due to immobilisation or sex hormone deficiency, osteomalacia, hyperostosis and osteopetrosis.

A method of treating hypoparathyroidism in a human DiGeorge syndrome subject comprises (a) implanting thymus tissue into the subject in an amount effective to treat the DiGeorge syndrome; and (b) implanting, preferably concurrently implanting, parathyroid tissue into the subject in an amount effective to treat the hypoparathyroidism.

The invention belongs to the field of medicinal chemistry, and particularly relates to a novel crystalline form A of doxercalciferol and a preparation method for the novel crystalline form A. The invention further comprises a pharmaceutical composition of the novel crystalline form A of doxercalciferol and an application of the composition for treating osteoporosis or secondary hyperparathyroidism. By virtue of Cu-Kalpha radiation, X-ray powder diffraction has diffraction peaks at positions where 2theta angles are 7.82, 8.51, 12.06, 13.01, 15.60, 17.05, 17.82, 18.71, 19.35, 20.06, 20.37, 20.62, 21.98, 22.68, 22.90, 23.81 and 24.79. The invention further discloses a technically improved scheme for preparing high purity doxercalciferol at the same time. The scheme is simple in step, easy to operate, short in consumed time and low in cost, and industrial large-scaled production is quite facilitated.

The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or its hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The present invention also includes an oral pharmaceutical powder comprising lanthanum carbonate or lanthanum carbonate hydrate and a pharmaceutically acceptable excipient. The oral pharmaceutical capsules and powders of the present invention can be administered to treat a patient at risk of or suffering from hyperphosphatemia, at risk of or suffering from chronic kidney disease (CKD), at risk of or suffering from soft tissue calcification associated with CKD, or at risk of or suffering from secondary hyperparathyroidism.

The present invention provides a dihydropyridazine-3,5-dione derivative or a salt thereof, or a solvate of the compound or the salt, a pharmaceutical drug, a pharmaceutical composition, a sodium-dependent phosphate transporter inhibitor, and a preventive and / or therapeutic agent for hyperphosphatemia, secondary hyperparathyroidism, chronic renal failure, chronic kidney disease, and arteriosclerosis associated with vascular calcification comprising the compound as an active ingredient, and a method for prevention and / or treatment.

Compounds of the formulaare useful in the treatment of various disorders including, but not limited to, cancer (tumor metathesis, tumorgenesis / tumor growth), angiogenesis (as in cancer, diabetic retinopathy, rheumatoid arthritis), restenosis (following balloon angioplasty or stent implantation), inflammation (as in rheumatoid arthritis, psoriasis), bone diseases (osteopenia induced by bone metastases, immobilization and glucocortocoid treatment, periodontal disease, hyperparathyroidism and rheumatoid arthritis), and as antiviral agents. Novel method of making compounds of formula I are also provided.

Described herein is a multiplex platform that uses ultrasmall nanoparticles (e.g., C dots and C' dots) to graphically differentiate specific nerves (e.g., sensory nerves vs. motor nerves) for nerve transplants and other surgeries. Also described herein is a multiplex platform that uses ultrasmall nanoparticles (e.g., C dots and C' dots) to graphically differentiate between different types of lymphnodes and / or lymphatic pathways, e.g., to safely and effectively perform vascularized lymph node transplantation in the treatment of lymphedema. Also described herein is a multiplex platform that uses ultrasmall nanoparticles (e.g., C dots and C' dots) to graphically differentiate parathyroid tissue.

The invention relates to the technical field of calcitriol, in particular to an oral solution containing calcitriol and a preparation method of the oral solution, and the oral solution containing calcitriol comprises the following components in parts by weight: 0.290-0.305 part of calcitriol; 29.7 to 30.3 parts of butyl hydroxy anisole; 29.8 to 30.2 parts of butylated hydroxytoluene (BHM); and 299987 to 300012 parts of medium chain triglycerides. The preparation method of the oral solution containing calcitriol comprises the following steps: S100, weighing: turning on a yellow light lamp in a weighing room, weighing calcitriol, medium chain triglyceride, butylated hydroxyanisole and butylated hydroxytoluene according to parts by weight, and carrying out double-person rechecking; compared with the prior art, the oral solution containing calcitriol has the following beneficial effects that the oral solution containing calcitriol can make up the blank in the field of treating secondary hyperparathyroidism of patients with moderate to severe chronic renal failure before dialysis and follow-up metabolic bone diseases and hypoparathyroidism in domestic children medication, and the clinical requirements are met.

The invention discloses a method and a system for identifying parathyroid hyperplasia in an ultrasonic image. The method comprises the following steps: acquiring a training sample comprising the ultrasonic image and a corresponding diagnosis result, wherein the ultrasonic image is an image obtained after ultrasonic imaging is carried out on a hyperparathyroidism area of a patient; carrying out data enhancement processing on the training sample by adopting a mixed gamma-CLAHE method; inputting the enhanced training sample into a Faster R-CNN network to obtain a trained network model; and inputting the neck ultrasonic image to be recognized into the trained Faster R-CNN model to obtain a recognition result output by the trained model. The method is high in recognition accuracy and high in speed, can help doctors to quickly find out organ positions and judge organ possibility from the perspective of image recognition, and improves efficiency for the doctors.

The invention relates to application of a molecular marker in diagnosing of parathyroid tumor, in particular to application of one or more combination parts which are selectively combined to the molecular marker in preparation of a reagent for authenticating the parathyroid tumor. The molecular marker is selected from CD24, HMOX1, VCAM1 or KCNA3.

The present invention relates to a parathyroid sensing system comprising: a modulator for generating a modulation signal having a predetermined frequency; a lock-in amplifier and a light source whichreceive information on the modulation signal; an excitation filter for transmitting, among light emitting from the light source, only excitation light that excites the parathyroid glands; a probe andan emission filter connected to the probe and selectively transmitting only autofluorescence emitting from the parathyroid glands; a near-infrared sensor for sensing the autofluorescence that has passed through the emission filter, and converting same into an electric signal; and a speaker for generating an alarm through the electric signal. By means of the present invention, the locations of theparathyroid glands may be precisely identified even when lights are turned on in an operating room, and convenience may be provided by alerting a surgeon by means of an alarm when the parathyroid glands are detected. In addition, the locations of the parathyroid glands may be precisely detected, even when the probe is not directly in contact with the parathyroid glands, by using the autofluorescence characteristics of the parathyroid glands.

The invention discloses an accurate intraoperative parathyroid gland recognition method and a detection device thereof. The detection device comprises a No. 22 needle, a 5ML sterile injector, a glassslide, a shell, a digital display angle gauge, a micro stepping motor, a rotating shaft, a gear, a sliding groove, a first clamping groove, a sliding plate, a rack, a first travel switch, a second travel switch, a second clamping groove, a close cover, a first switch, a second switch and a storage battery. The accurate intraoperative parathyroid gland recognition method and the detection device thereof have the advantages that by the angle detection and display device, accuracy of inclined puncture angles can be improved, and follow-up extraction success rate can be increased; by an internal electric pumping mechanism, operation of medical workers is facilitated and high efficiency in pumping is improved; through coordination between multiple clamping grooves and limiting and fixing devices, the detection device can be used with the 5ML sterile injector in the prior art, and an electric mechanism can be reused sterilely; operation burdens of the medical workers are relieved, detectioncost is reduced, and clinical popularization and application are benefited.

The present invention relates to a real-time parathyroid imaging device, and a real-time parathyroid imaging device for displaying only a parathyroid in a thyroid with a separate mark, the real-time parathyroid imaging device including: a light source configured to emit light to a thyroid and excite a parathyroid; a detector configured to detect an emission spectrum of the parathyroid excited and emitted by the light source; an excitation filter disposed in front of the light source; and an emission filter disposed in front of the detector. When central Compartment Neck Dissection (CCND) for thyroidectomy is performed, the present invention clearly marks a parathyroid by an autofluorescent image, thereby allowing a surgeon to more simply and safely perform the CCND while leaving the parathyroid.

The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or lanthanum hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The capsules of the present invention dissolve at a similar rate before and after storage. The oral pharmaceutical capsules of the present invention can be administered to treat a patient at risk for or suffering from hyperphosphatemia, at risk for or suffering from chronic kidney disease (CKD), at risk for or suffering from soft tissue calcification associated with CKD, or at risk for or suffering from secondary hyperparathyroidism.

The invention discloses a novel parathyroid gland detection device which is composed of a probe, a handle, an external optical fiber cable and a host, a probe lens is arranged at the top end of the probe, the host comprises a cassette, an internal optical fiber cable, a laser emission unit, a fluorescence detection unit and a controller, and the external optical fiber cable and the internal optical fiber cable both adopt a single optical fiber design. The cassette comprises a laser light source, a photoelectric sensor, a first lens and a second lens, the laser light source is provided with a laser filtering cover, the surface of the photoelectric sensor is covered with a fluorescent filtering film, and the laser light source is placed on the photoelectric sensor. The parathyroid gland detection device is simple in structure, laser density can be improved, fluorescence signal intensity is enhanced, and accordingly parathyroid gland detection and recognition rate is improved.

The invention relates to lanthanum hydroxide which has the functions of preparing and curing chronic renal failure (CRF), hyperphosphatemia or / and hyperparathyroidism (SHPT), vitamin D metabolic block, renal osteopathy and cardiovascular system calcification drugs, wherein the lanthanum hydroxide is nanometer lanthanum hydroxide, and daily dose of the lanthanum hydroxide or the nanometer lanthanum hydroxide is 600mg to 7800mg..

The invention discloses a preparation method of a human parathyroid gland single-cell suspension. The preparation method comprises the following steps of taking parathyroid gland tissues, washing, andcutting into pieces; adding IV-type collagenase, uniformly mixing and digesting; stopping digestion, filtering, centrifuging, removing supernatant, and adding DPBS for suspension; performing filtering, centrifuging, removing supernatant, and adding DPBS for suspension; adding erythrocyte lysate to remove erythrocytes, centrifuging, removing supernatant, adding DPBS to clean the cells twice, removing the supernatant, and then adding DPBS to suspend to obtain the parathyroid gland single-cell suspension. The invention also discloses a detection method of the human parathyroid gland single-cellsuspension. The detection method comprises the following steps of carrying out culturing on the human parathyroid gland single-cell suspension; observing the growth state of primary and passage first-generation cells every day; and extracting RNA of the passage first-generation cells, and detecting RNA of a parathyroid gland cell specific marker by using a PCR method. The preparation method of thehuman parathyroid gland single-cell suspension can stably and reliably digest cells, and the obtained cells are high in content and activity.

The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or its hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The present invention also includes an oral pharmaceutical powder comprising lanthanum carbonate or lanthanum carbonate hydrate and a pharmaceutically acceptable excipient. The oral pharmaceutical capsules and powders of the present invention can be administered to treat a patient at risk of or suffering from hyperphosphatemia, at risk of or suffering from chronic kidney disease (CKD), at risk of or suffering from soft tissue calcification associated with CKD, or at risk of or suffering from secondary hyperparathyroidism.

The invention provides a preparation method of a falecalcitriol tablet, and belongs to the technical field of medicines. The falecalcitriol tablet disclosed by the invention is prepared from falecalcitriol, a sustained-release material, a filling agent, a lubricating agent and a 95% ethanol solution. The main component of the pharmaceutical composition is falecalcitriol which belongs to vitamin D3analogues, can regulate calcium metabolism and resist rickets, and is used for treating parathyroid hypofunction. The method provides a sustained-release preparation which is safe, effective, stablein quality, low in cost, low in administration frequency, high in patient compliance and capable of slowly releasing drugs.

The invention discloses a parathyroid detection method. The method involves an operating bed, an equipment table and a handle probe, and further involves a transmitting optical fiber, a detection optical fiber and a pedal switch, wherein the equipment table is assembled on one side of the operating bed, an integrated display is assembled on the top of the equipment table, a complete set of controller is assembled on the back of the integrated display, a main controller is arranged at the bottom of the integrated display through a bolt, the handle probe is assembled on one side of the complete set of controller through a wire, a probe is arranged at the detection end of the handle probe, the transmitting optical fiber and the detection optical fiber are inserted into the end of the probe, a near-infrared camera is arranged on the probe through a bolt, the probing and shooting end of the near-infrared camera is connected with the tail end of the detection optical fiber, and a probe switch is assembled on the handle probe. According to the method, by means of an infrared imaging instrument, the confidence of a surgeon on parathyroid identification is obviously improved, the operation time is shortened to a certain degree, the operation difficulty is reduced, and fine operation in an operation is well facilitated.

The invention discloses a glycoside enrichment of Ligustrum lucidum, the preparation method of which comprises the following steps: adding 10-14 times of ethanol with a volume concentration of 50-80% to Ligustrum lucidum, refluxing and extracting for 1-3h, filtering, and Add 8 times the amount of ethanol with a volume concentration of 50-80% to the residue, reflux for extraction for 1-3 hours, filter, combine the two filtrates, recover the solvent, add an appropriate amount of ethyl acetate for extraction, discard the ethyl acetate layer, and add water to the water layer to saturate Extract with n-butanol, combine the water-saturated n-butanol layers, concentrate, and vacuum-dry to obtain the glycoside enrichment of Ligustrum lucidum. The invention also discloses the application of the Ligustrum lucidum glucoside enrichment in the preparation of medicine for treating hypoparathyroidism.

The invention discloses a side gland surgical treatment auxiliary detection method, which comprises an operating bed, an equipment table and a handle probe, and further comprises a transmitting optical fiber, a detection optical fiber and a pedal switch, the equipment table is assembled on one side of the operating bed, an integrated display is assembled on the top of the equipment table, and a complete set of controller is assembled on the back of the integrated display. A main controller is arranged at the bottom of the integrated display through bolts, a handle probe is assembled on one side of the controller set through a wire, a probe is arranged at the detection end of the handle probe, a transmitting optical fiber and a detection optical fiber are inserted into the end of the probe, a near-infrared camera is installed on the probe through bolts, and a camera is installed on the near-infrared camera. The probing and shooting end of the near-infrared camera is connected with the tail end of the detection optical fiber, and a probe switch is assembled on the handle probe. By means of the infrared imaging instrument, the confidence of a surgeon on parathyroid gland identification is obviously improved, the operation time is shortened to a certain degree, the operation difficulty is reduced, and fine operation in an operation is better facilitated.

The present invention provides a compound represented by the following general formula (I):or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing such a compound, and the like. The compound or a pharmaceutically acceptable salt thereof, the pharmaceutical composition containing such a compound, or the like is useful as a medicine or the like for therapy of benign prostatic hyperplasia, cancer, osteoporosis, psoriasis, secondary hyperparathyroidism, chronic glomerulonephritis, lupus nephritis and / or diabetic nephropathy and the like.

The invention relates to the technical field of biological medicines, in particular to a parathyroid carcinoma related gene mutation site and a diagnosis product thereof. The invention discloses the gene mutation site for diagnosing parathyroid carcinoma and application of the gene mutation site in preparation of a parathyroid carcinoma diagnostic reagent or kit. By adopting the kit prepared by the invention, the accuracy of early diagnosis of clinical parathyroid carcinoma can be improved, so that a patient can obtain more accurate treatment measures, and a better treatment effect is obtained. Meanwhile, a new direction is provided for a drug target for early prevention and treatment of parathyroid carcinoma, and research and development of innovative drugs are promoted.

A compound as represented by formula (I), and optical isomers, solvates, pharmaceutically-acceptable salts, or prodrugs thereof. The present invention has urate transporter 1 (URAT1) inhibitory activity, can be used for treatment of gout and hyperuricemia, and can also be used for treatment of diseases related to abnormal URAT1 activity, such as recurrent gout attacks, gouty arthritis, hypertension, cardiovascular diseases, coronary heart disease, Lesch-Nyhan syndrome, Kearns-Sayre syndrome, kidney diseases, kidney stones, kidney failure, joint inflammations, arthritis, urolithiasis, lead poisoning, hyperparathyroidism, psoriasis, sarcoidosis, or hypoxanthine-guanine phosphoribosyltransferase deficiency. (I)

The invention discloses a parathyroid gland probe which comprises a probe box, a detection probe rod and a detection head and further comprises a detection controller and a main controller, the detection probe rod is provided with the probe box, a detection connector is arranged at the bottom end of the detection probe rod, the detection head is assembled at the bottom of the detection connector and comprises a head sleeve and a detection core, the detection core comprises a lower mounting head, an upper mounting head, a transmitting fiber and a receiving fiber, the two ends of the transmitting fiber and the two ends of the receiving fiber are inserted into the lower mounting head and the upper mounting head respectively, a detection controller is assembled in the detection probe rod, the detection controller comprises an auxiliary processor, a modulator, a demodulator, a near-infrared camera, a laser transmitter and a battery, the detection controller further comprises a storage module and a transmission module, and a main controller is assembled in the probe box. The parathyroid gland probe is simple to operate and convenient to carry, facilitates more efficient positioning of parathyroid gland pathological areas by medical staff, and greatly improves the efficiency and success probability of parathyroid gland treatment.

The present invention relates to the technical field of medical equipment, and it relates to a medical parathyroid tissue syringe, which includes a syringe, a piston, a motor, a blade and a driving mechanism; The inner wall is circumferentially sealed, and the push-pull rod is used to drive the plug body to move axially along the inner wall of the injection barrel; one end of the plug body is provided with a receiving groove; the bottom surface of the receiving groove is provided with a through hole; the motor includes a body and a On the motor shaft, one end of the motor shaft is used to pass through the through hole and connect with the blade; the driving mechanism is used to drive the body to move relative to the plug body, so as to drive the blade to extend or retract into the accommodation groove; and when retracting into the accommodation groove , the blade is in sealing fit with the groove wall of the accommodating groove in the circumferential direction. According to the technical solution of the present invention, when injecting the parathyroid homogenate, the piston can be pushed to the bottom of the injection cylinder, thereby reducing the residue of the parathyroid homogenate in the injection cylinder.